3 recruiting, 1 completed. 4 Phase 2, 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 4 | Recruiting 3, Completed 1 |
| Phase 1 | 2 | Recruiting 2 |
Follow Refractory Large B-cell Lymphoma: new trials by email Literature Review of Refractory Large B-cell Lymphoma trials Research Report on Refractory Large B-cell Lymphoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Outpatient Epcoritamab in Large B-cell Lymphoma Epcoritamab, Rituximab combined with cyclophosphamide, vincristine, and prednisone, Rituximab combined with cyclophosphamide, doxorubicin, vincristine, and prednisone - Relapsed Large B-cell Lymphoma, Refractory Large B-cell Lymphoma | Phase 2 | Recruiting | Massachusetts General Hospital | 40 | 2025-06-05 | 2026-08-13 |
| Study of Safety and Efficacy of TC011 in the Relapsed/Refractory Large B Cell Non-Hodgkin Lymphoma Patients TC011 - Relapsed Large B-cell Lymphoma, Refractory Large B-cell Lymphoma | Phase 1 / Phase 2 | Recruiting | TICAROS Co., Ltd. | 98 | 2023-08-03 | 2026-03-16 |
| Study of Efficacy and Safety of CRC01 in Adult Large B-cell Lymphoma and B-cell Acute Lymphoblastic Leukemia Patients CRC01, Fludarabine, Cyclophosphamide - Relapsed Large B-cell Lymphoma, Refractory Large B-cell Lymphoma | Phase 1 / Phase 2 | Recruiting | Curocell Inc. | 91 | 2021-03-02 | 2026-07-01 |
| Safety and Efficacy of Axicabtagene Ciloleucel in Combination With Rituximab in Participants With Refractory Large B-Cell Lymphoma Axicabtagene Ciloleucel, Rituximab, Fludarabine - Refractory Large B-cell Lymphoma | Phase 2 | Completed | Kite, A Gilead Company | 27 | 2019-11-05 | 2024-02-20 |
Lymphoma, Large B-Cell, Diffuse (2)
Hemic and Lymphatic Diseases (2) · Immune System Diseases (2) · Immunoproliferative Disorders (2) · Lymphatic Diseases (2) · Lymphoma (2) · Lymphoma, B-Cell (2) · Lymphoma, Non-Hodgkin (2) · Lymphoproliferative Disorders (2) · Neoplasms (2) · Neoplasms by Histologic Type (2)
Cyclophosphamide (3) · fludarabine (2) · Doxorubicin (1) · Prednisone (1) · Rituximab (1) · Vincristine (1) · axicabtagene ciloleucel (1)
Curocell Inc. (1) · Kite, A Gilead Company (1) · Massachusetts General Hospital (1) · TICAROS Co., Ltd. (1)
South Korea (2) · United States (2)
PMID 34515338, PMID 34628052, PMID 41492094, PMID 42284198
2019 (1)